Scott Wilhelm

Summary

Affiliation: Bayer HealthCare
Country: USA

Publications

  1. ncbi Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor
    Jacques Dumas
    Department of Chemistry Research, Bayer Research Center, 400 Morgan Lane, West Haven, CT 06516, USA
    Bioorg Med Chem Lett 12:1559-62. 2002
  2. ncbi BAY 43-9006: preclinical data
    Scott Wilhelm
    Bayer Research Center, Bayer Corporation, Pharmaceutical Division, 400 Morgan Lane, West Haven, CT 06516, USA
    Curr Pharm Des 8:2255-7. 2002
  3. ncbi BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Scott M Wilhelm
    Bayer Pharmaceuticals Corporation, West Haven, Connecticut 06516, USA
    Cancer Res 64:7099-109. 2004
  4. ncbi Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature
    Lila Adnane
    Department of Cancer Research, Bayer Pharmaceutical Corp, West Haven, Connecticut, USA
    Methods Enzymol 407:597-612. 2006
  5. ncbi Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
    Scott Wilhelm
    Department of Cancer Research, Bayer Pharmaceuticals Corp, West Haven, Connecticut 06516, USA
    Nat Rev Drug Discov 5:835-44. 2006
  6. ncbi Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
    Li Liu
    Department of Cancer Biology, Bayer HealthCare Pharmaceuticals, West Haven, Connecticut 06516, USA
    Cancer Res 66:11851-8. 2006
  7. ncbi Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
    Yong S Chang
    Department of Protein Therapeutics, Bayer Research Center, Bayer HealthCare, Pharmaceuticals, 400 Morgan Lane, West Haven, CT 06516, USA
    Cancer Chemother Pharmacol 59:561-74. 2007
  8. ncbi SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer
    Philip Wickens
    Department of Chemistry Research, Bayer Research Center, 400 Morgan Lane, West Haven, CT 06516, USA
    Bioorg Med Chem Lett 17:4378-81. 2007
  9. ncbi Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants
    Teresa Guida
    Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita di Napoli Federico II, Naples, Italy
    Clin Cancer Res 13:3363-9. 2007
  10. ncbi Recent advances in the research and development of RAF kinase inhibitors
    Roger A Smith
    Bayer Research Center, Bayer Pharmaceuticals Corporation, West Haven, CT 06516, USA
    Curr Top Med Chem 6:1071-89. 2006

Collaborators

  • David Gunn
  • Li Liu
  • Pamela A Trail
  • Lei Wang
  • Yong S Chang
  • Michael Brands
  • Leonard E Post
  • Gideon Bollag
  • Liu Li
  • M Santoro
  • R A Smith
  • Christopher A Carter
  • J M Llovet
  • J Dumas
  • Francesca Carlomagno
  • Teresa Guida
  • Giuliana Salvatore
  • Elizabeth Sullivan
  • Philip Wickens
  • Ian Taylor
  • Suresh Anaganti
  • Giancarlo Troncone
  • Lila Adnane
  • Livia Provitera
  • Julie Dixon
  • Debbie Braun
  • Antonella Bacchiocchi
  • Charles Kreiman
  • Richard Gedrich
  • Donald Bierer
  • Timothy Lowinger
  • Harold Kluender
  • Chih Yuan Chuang
  • Ronda Ott-Morgan
  • Xiaomei Zhang
  • Uday Khire
  • William J Scott
  • Don Bankston
  • Catherine Brennan
  • Ellalahewage Kumarasinghe
  • Louise Perkins
  • Robert Schoenleber
  • Zhenqiu Hong
  • Barton Phillips
  • Benjamin Jones
  • Melissa S Brown
  • Joan Levy
  • Furahi Achebe
  • Xiuying Sun
  • Gloria Hofilena
  • Ryan Sheeler
  • Tim Housley
  • Mingbao Zhang
  • Istvan Enyedy
  • Mark Miglarese
  • Aniko Redman
  • Rosa Marina Melillo
  • Stefano Pepe
  • Tito Claudio Nappi
  • Valentina De Falco
  • Paolo Salerno

Detail Information

Publications14

  1. ncbi Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor
    Jacques Dumas
    Department of Chemistry Research, Bayer Research Center, 400 Morgan Lane, West Haven, CT 06516, USA
    Bioorg Med Chem Lett 12:1559-62. 2002
    ..This compound is orally active in two acute models of cytokine release (TNF-induced IL-6 and LPS-induced TNF) and a chronic model of arthritis (20-day murine collagen-induced arthritis)...
  2. ncbi BAY 43-9006: preclinical data
    Scott Wilhelm
    Bayer Research Center, Bayer Corporation, Pharmaceutical Division, 400 Morgan Lane, West Haven, CT 06516, USA
    Curr Pharm Des 8:2255-7. 2002
    ..In vitro and in vivo experiments were designed to demonstrate effective blockade of the Raf/MEK/ERK signaling pathway in tumor cells and for anti tumor efficacy in human xenograft models...
  3. ncbi BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
    Scott M Wilhelm
    Bayer Pharmaceuticals Corporation, West Haven, Connecticut 06516, USA
    Cancer Res 64:7099-109. 2004
    ..These data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis...
  4. ncbi Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature
    Lila Adnane
    Department of Cancer Research, Bayer Pharmaceutical Corp, West Haven, Connecticut, USA
    Methods Enzymol 407:597-612. 2006
    ..This agent is currently being evaluated in phase III clinical trials in renal cell and hepatocellular carcinomas...
  5. ncbi Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
    Scott Wilhelm
    Department of Cancer Research, Bayer Pharmaceuticals Corp, West Haven, Connecticut 06516, USA
    Nat Rev Drug Discov 5:835-44. 2006
    ....
  6. ncbi Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
    Li Liu
    Department of Cancer Biology, Bayer HealthCare Pharmaceuticals, West Haven, Connecticut 06516, USA
    Cancer Res 66:11851-8. 2006
    ....
  7. ncbi Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
    Yong S Chang
    Department of Protein Therapeutics, Bayer Research Center, Bayer HealthCare, Pharmaceuticals, 400 Morgan Lane, West Haven, CT 06516, USA
    Cancer Chemother Pharmacol 59:561-74. 2007
    ..The effect of sorafenib on tumor growth and tumor histology was assessed in both ectopic and orthotopic mouse models of RCC...
  8. ncbi SAR of a novel 'Anthranilamide Like' series of VEGFR-2, multi protein kinase inhibitors for the treatment of cancer
    Philip Wickens
    Department of Chemistry Research, Bayer Research Center, 400 Morgan Lane, West Haven, CT 06516, USA
    Bioorg Med Chem Lett 17:4378-81. 2007
    ..Corresponding thiophene, pyrazole, and thiazole core analogs were prepared as VEGFR-2 inhibitors with c-KIT, and B-RAF activity. Compounds in the phenyl, thiophene, and thiazole series are in vivo active...
  9. ncbi Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants
    Teresa Guida
    Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita di Napoli Federico II, Naples, Italy
    Clin Cancer Res 13:3363-9. 2007
    ..The aim of this study was to evaluate whether sorafenib (BAY 43-9006), a multitargeted ATP-competitive inhibitor of KIT and PDGFR, was active against imatinib-resistant KIT and PDGFRbeta kinases...
  10. ncbi Recent advances in the research and development of RAF kinase inhibitors
    Roger A Smith
    Bayer Research Center, Bayer Pharmaceuticals Corporation, West Haven, CT 06516, USA
    Curr Top Med Chem 6:1071-89. 2006
    ..Preclinical and clinical data for the RAF kinase inhibitor sorafenib (BAY 43-9006 tosylate), that was recently approved in the US for the treatment of advanced renal cell carcinoma, are also outlined...
  11. ncbi BRAF is a therapeutic target in aggressive thyroid carcinoma
    Giuliana Salvatore
    Istituto di Endocrinologia ed Oncologia Sperimentale del Consiglio Nazionale delle Ricerche, c o Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita di Napoli Federico II, Naples, Italy
    Clin Cancer Res 12:1623-9. 2006
    ..In papillary thyroid carcinomas, this mutation is associated with an unfavorable clinicopathologic outcome. Our aim was to exploit BRAF as a potential therapeutic target for thyroid carcinoma...
  12. ncbi BAY 43-9006 inhibition of oncogenic RET mutants
    Francesca Carlomagno
    Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita di Napoli Federico II, Naples, Italy
    J Natl Cancer Inst 98:326-34. 2006
    ..We evaluated whether the biaryl urea BAY 43-9006, which is known to inhibit several other tyrosine kinases, blocks RET kinase function and oncogenic activity...
  13. doi Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
    Scott M Wilhelm
    Bayer HealthCare Pharmaceuticals, 340 Changebridge Road, P O Box 1000, Montville, NJ 07045 1000, USA
    Mol Cancer Ther 7:3129-40. 2008
    ..In particular, preclinical evidence that supports the different mechanisms of action of sorafenib is discussed...
  14. ncbi Evaluation and management of incidental thyroid nodules in patients with another primary malignancy
    Scott M Wilhelm
    Department of Surgery, University Hospitals Case Medical Center, Cleveland, Ohio 44106, USA
    Surgery 142:581-6; discussion 586-7. 2007
    ..We sought to determine the rate of malignancy in incidental thyroid nodules in patients with other malignancies, and examine the accuracy of ultrasound (US) versus computed tomography (CT) in determining nodule size...